Registre HEAR, Healthcare European Amyloidosis Registry
This is a non-interventional, prospective, retrospective, non-comparative, multi-center study. In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up. This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis. Three cohorts will be identified: the HEAR (Healthcare European Amyloidosis Registry)-Retrospective Cohort, the HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort and the HEAR (Healthcare European Amyloidosis Registry)-Prospective Cohort.
• Patients must meet all of the following inclusion criteria to be included in the study:
‣ Major patient
⁃ Protected adult patient (guardianship or curatorship)
• Prospective Cohort:
• Patients referred or who have been referred to the participating centre for suspected amyloidosis.
• Patient who signed the patient information Prospective Cohort note
• Retro-prospective Cohort:
• Patient already followed in the center with a confirmed diagnosis of amyloidosis Patient who signed the retro-prospective cohort patient information note
• Retrospective cohort:
∙ Deceased patients followed in the center with a confirmed diagnosis of amyloidosis
∙ Study participants will not be compensated for their participation